Phase 3 trial of hepatitis D treatment combo enrolls 1st patient
The first patient has been enrolled in ECLIPSE 1, a Phase 3 clinical trial testing Vir Biotechnology’s experimental combination of tobevibart and elebsiran in adults…
Hepatitis
Bemnifosbuvir-ruzasvir Phase 3 trials in hepatitis C launch in April
Atea Pharmaceuticals plans to launch two parallel Phase 3 trials soon to test its investigational combination therapy of bemnifosbuvir and ruzasvir for people with…
Researchers uncover how hepatitis B virus can persist in liver cells
Researchers have discovered a key mechanism that allows the hepatitis B virus (HBV) to infect and persist in liver cells, in a new study…
Hepatitis C telemedicine approach for opioid users receives award
A program using a telemedicine approach to treat hepatitis C in people with opioid use disorder that resulted in the cure of more than…
Hepatitis B gene-editing therapy PBGENE-HBV shows early promise
A single dose of Precision BioSciences’ investigational gene-editing therapy PBGENE-HBV was well tolerated and showed early signs of antiviral activity among three adults with…
Dosing complete in Phase 2b trial of AHB-137 for hepatitis B
A Phase 2b clinical trial testing AusperBio’s investigational therapy AHB-137 in people with chronic hepatitis B has completed dosing and is now unblinded,…
Virtual clinic for liver diseases opens to US patients
A virtual clinic for liver diseases, including hepatitis, has begun treating patients. The LiverRight Hepatology Clinic offers same-week video visits to adults who…
HBV vaccine birth dose not tied to premature babies’ lung disease risk
Babies born extremely prematurely who were given a dose of the hepatitis B virus (HBV) vaccine within a day of being born were not…
FDA grants breakthrough designation to hepatitis D treatment
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to brelovitug, a hepatitis D treatment that’s being developed by Bluejay…
Trial of HBV treatment candidate now enrolling final patient group
Virion Therapeutics has announced that it’s completed enrollment for the first two groups of adults with chronic hepatitis B virus (HBV) infection in…
